Peter Priester

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text

Medicine, Oncology, Pharmacology +17

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report

Jindřich Kopecký, Ondřej Kubeček, Tomáš Geryk et al. · Journal of Medical Case Reports · 2018 · 56 citations · Full text

Life Sciences, Immunology, Oncology +17

Aplastic Anemia as a Cause of Death in a Patient with Glioblastoma Multiforme Treated with Temozolomide

Jindřich Kopecký, Peter Priester, Ladislav Slováček et al. · Strahlentherapie und Onkologie · 2010 · 21 citations

Medicine, Hematology, Oncology +13

Depression symptoms and health-related quality of life among patients with metastatic breast cancer in programme of palliative cancer care

Ladislav Slováček, Birgita Slováčková, Iva Slánská et al. · Neoplasma · 2009 · 18 citations

Medicine, Oncology, Palliative Care +16